VEGF inhibitors may augment immunotherapy efficacy for first-line renal cell carcinoma – Healio
|
VEGF inhibitors may augment immunotherapy efficacy for first-line renal cell carcinoma
Healio Early-phase clinical trials have shown high response rates with VEGF TKIs combined with immunotherapy in the first-line setting, and some patients have achieved durable responses. However, it will be important to better understand resistance patterns … |
